AI assistant
Lyell Immunopharma, Inc. — Director's Dealing 2025
Feb 27, 2025
33362_dirs_2025-02-26_d274b933-f9a6-480a-951c-c133d3689f48.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-02-10
Reporting Person: Seely Lynn (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-10 | Common Stock | A | 337500 | — | Acquired | 537500 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-10 | Option (right to buy) | $0.5535 | A | 1350000 | Acquired | 2035-02-09 | Common Stock (1350000) | Direct |
| 2025-02-10 | Option (right to buy) | $0.5535 | A | 168750 | Acquired | 2035-02-09 | Common Stock (168750) | Direct |
Footnotes
F1: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
F2: 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
F3: The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon
the achievement of specified performance criteria.